Vesicular acetylcholine transporter density and Alzheimer's disease

Neurobiology of Aging

Volumn 18, Issue 4, 1997, Pages 407-413

  Efange, S M N ^a,b   Garland, E M ^b   Staley, J K ^b   Khare, A B ^a   Mash, D C ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

(+) Meta 125I iodobenzyltrozamicol; Aging; Alzheimer's disease; Cholinergic innervation; Radioligands; Transporter; Vesamicol; Vesamicol receptor; Vesicular acetylcholine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINE TRANSPORTER; ACETYLCHOLINESTERASE; BIOCHEMICAL MARKER; CHOLINE ACETYLTRANSFERASE; RADIOLIGAND; UNCLASSIFIED DRUG; VESAMICOL;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PARASYMPATHETIC INNERVATION; PRIORITY JOURNAL; RECEPTOR DENSITY; SYNAPSE VESICLE; TEMPORAL CORTEX;

ACETYLCHOLINE; ADULT; AFFINITY LABELS; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CARRIER PROTEINS; CHOLINE O-ACETYLTRANSFERASE; FEMALE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PIPERIDINES; RECEPTORS, CHOLINERGIC; TEMPORAL LOBE; VESICULAR ACETYLCHOLINE TRANSPORT PROTEINS; VESICULAR TRANSPORT PROTEINS;

EID: 0030770648     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(97)00038-9     Document Type: Article

References (59)

1. Alfonso A., Grundahl K., Duerr J. S., Han H. P., Rand J. B. The Caenorhabditis elegans unc-17 gene A putative vesicular acetylcholine transporter . Science. 261:1993;617-619.
2. 3H]Vesamicol binding in brain Autoradiographic distribution, pharmacology, and effect of cholinergic lesions . Synapse. 2:1988;486-493.
3. Baratti C. M., Huygens P., Mino J., Merlo A., Gardella J. Memory facilitation with post-trial oxetremorine and physostigmine in mice. Psychopharmacology. 64:1979;85-88.
4. Berrard S., Varoqui H., Cervini R., Israel M., Mallet J., Diebler M.-F. Coregulation of two embedded gene products, choline acetyltransferase and the vesicular acetylcholine transporter. J. Neurochem. 65:1995;939-942.
5. Berse B., Blusztajn J. K. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor α, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J. Biol. Chem. 270:1995;22101-22104.
6. Caine E. D., Weingartner H., Ludlow D. L., Cudahy E. A., Wehry S. Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology. 74:1981;74-80.
7. Carlsson A., Adolfsson R., Aquilonius S. M., Gottfries C. G., Oreland L., Svennerholm L., Winblad B. Biogenic amines in brain in normal aging, senile dementia and chronic alcoholism. Adv. Biochem. Psychopharmacol. 23:1980;295-304.
8. Cervini E. D., Houhou L., Pradat P.-F., Bejanin S., Mallet J., Berrard S. Specific vesicular acetylcholine transporter promoters lie within the first intron of the rat choline acetyltransferase gene. J. Biol. Chem. 270:1995;24654-24657.
9. Davis K. L., Mohs R. C., Tinklenberg J. R., Pfefferbaum A., Hollister L. E., Kopell B. S. Physostigmine Improvement on long-term memory processes in normal subjects . Science. 201:1978;272-274.
10. Decker M. W. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res. Rev. 12:1987;423-438.
11. Drachman D. A., Leavitt J. Human memory and the cholinergic system. Arch. Neurol. 30:1974;113-121.
12. Drachman D. A. Memory and cognitive function in man does the cholinergic system have a specific role? Neurology. 27:1977;783-790.
13. Efange S. M. N., Dutta A. K., Michelson R. H., Kung H. F., Thomas J. R., Billings J., Boudreau R. J. Radioiodinated 2-Hydroxy-3-(4-iodophenyl)-1-(4-phenylpiperidinyl)propane Potential radiotracer for mapping central cholinergic innervation in vivo . Nucleic Med. Biol. 19:1992;337-348.
14. Efange S. M. N., Khare A., Parsons S. M., Bau R., Metzenthin T. Non-symmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage. J. Med. Chem. 36:1993;985-989.
15. Efange S. M. N., Khare A. B., Foulon C., Akella S. K., Parsons S. M. Spirovesamicols Conformationally restricted analogs of 2-(4-phenylpiperidino)cyclohexanol (vesamicol, AH5183) as potential modulators of presynaptic cholinergic function . J. Med. Chem. 37:1994;2574-2582.
16. Efange S. M. N., Langason R. B., Khare A. B. Age-related diminution of dopamine antagonist-stimulated vesamicol receptor binding. J. Nucleic Med. 37:1996;1192-1197.
17. Efange S. M. N., Langason R. B., Khare A. B. Comparative tissue distribution of conformationally restricted radioiodinated vesamicol receptor ligands. Nucleic Med. Biol. 22:1995;437-444.
18. 2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat Possible implications for Parkinson's disease . Life Sci. 58:1996;1367-1375.
19. 18F]FBT) molecular decomposition-reconstitution approach to vesamicol receptor radioligands . Appl. Radiat. Isot. 45:1994;465-472.
20. Efange S. M. N., Mach R. H., Smith C. R., Khare A. B., Foulon C., Akella S. K., Childers S. R., Parsons S. M. Vesamicol analogues as sigma ligands Molecular determinants of selectivity at the vesamicol receptor . Biochem. Pharmacol. 49:1995;791-797.
21. Efange S. M. N., Mash D. C., Basile M. J., Pablo J., Kung H. F., Billings J., Michelson R. H., Thomas J. R. The vesamicol receptor (VR) Radioligand selectivity and the detection of central cholinergic hypofunction . J. Labeled Compd. Radiopharm. Spec. Symp. 32:1992;311-312.
22. 125I]MIBT) Potential radiotracer for mapping central cholinergic innervation . J. Med. Chem. 36:1993;1754-1760.
23. Erickson J. D., Varoqui H., Schafer M. K.-H., Modi W., Diebler M.-F., Weihe E., Rand J., Eiden L. E., Bonner T. I., Usdin T. B. cholinergic. J. Biol. Chem. 269:1994;21929-21932.
24. Flood J. F., Landry D. W., Jarvik M. Cholinergic receptor interactions and their effects on long-term processing. Brain Res. 215:1981;177-185.
25. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J. Neurochem. 24:1975;407-409.
26. Gilmor M. L., Nash N. R., Roghani A., Edwards R. H., Yi H., Hersch S. M., Levey A. I. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J. Neurosci. 16:1996;2179-2190.
27. Hicks B. W., Rogers G. A., Parsons S. M. Purification and characterization of a nonvesicular vesamicol-binding protein from electric organ and demonstration of a related protein in mammalian brain. J. Neurochem. 57:1991;509-519.
28. Holley L. A., Miller J. A., Chmielewski P. A., Dudchenko P., Sarter M. Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission. Brain Res. 610:1993;181-193.
29. Jung Y.-W., Frey K. A., Mulholland G. K., del Rosario R., Sherman P. S., Raffel D. M., Van Dort M. E., Kuhl D. E., Gildersleeve D. L., Wieland D. M. Vesamicol receptor mapping of brain cholinergic neurons with radioiodine-labeled positional isomers of benzovesamicol. J. Med. Chem. 39:1996;3331-3342.
30. Jung Y.-W., van Dort M. E., Gildersleeve D. L., Wieland D. M. A radiotracer for mapping cholinergic neurons of the brain. J. Med. Chem. 33:1990;2065-2068.
31. Kilbourn M. R., Jung Y.-W., Haka M. S., Gildersleeve D. L., Kuhl D. E., Wieland D. M. Mouse brain distribution of a carbon-11 labeled vesamicol derivative Presynaptic marker of cholinergic neurons . Life Sci. 47:1990;1955-1963.
32. 3H]Vesamicol binding in human brain cholinergic deficiency disorders. Neurosci. Lett. 117:1990;347-352.
33. Kuhl D. E., Koeppe R. A., Fessler J. A., Minoshima S., Ackermann R. J., Carey J. E., Gildersleeve D. L., Frey K. A., Wieland D. M. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J. Nucleic Med. 35:1994;405-410.
34. Kuhl D. E., Minoshima S., Fessler J. A., Frey K. A., Foster N. L., Ficaro E. P., Wieland D. M., Koeppe R. A. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease and Parkinson's disease. Ann. Neurol. 40:1996;399-410.
35. Marien M. R., Parsons S. M., Altar C. A. Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183). Proc. Natl. Acad. Sci. USA. 84:1987;876-880.
36. Mesulam M.-M., Mufson E. J., Levey A. I., Wainer A. I. Cholinergic innervation of cortex by the basal forebrain cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey . J. Comp. Neurol. 214:1983;170-197.
37. Molchan S. E., Mellow A. M., Lawlor B. A., Weingartner H. J., Cohen R. M., Cohen M. R., Sunderland T. TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology. 100:1990;84-89.
38. Mountjoy C. Q. Correlations between neuropathological and neurochemical changes. Br. Med. Bull. 42:1986;81-85.
39. Mountjoy C. Q., Rossor M. N., Iverson L. L., Roth M. Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain. 107:1984;507-518.
40. 18F]Fluorobenzyl-ABV a new potential marker for central cholinergic presynaptic sites . J. Nucl. Med. 32:(Suppl):1991;994.
41. 18F]fluoroethoxy-benzovesamicol (FEOBV): a new tracer for mapping cholinergic neurons in vivo. Abstr. IXth International Symposium on Radiopharmaceutical Chemistry, 487-488; 1992.
42. Parsons S. M., Prior C., Marshall I. G. Acetylcholine transport, storage and release. Int. Rev. Neurobiol. 35:1993;279-390.
43. Pearson R. C. A., Sofroniew M. V., Cuello A. C., Powell T. P. S., Eckenstein F., Esiri M. M., Wilcock G. K. Persistence of cholinergic neurons in the basal nucleus in a brain with SDAT demonstrated by immunohistochemical staining for CAT. Brain Res. 289:1983;375-379.
44. Perry E. K. The cholinergic system in old age and Alzheimer's disease. Age Ageing. 9:1980;1-8.
45. Perry E. K., Tomlinson B. E., Blessed G., Bergmann K., Gibson P. H., Perry R. H. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia. Br. Med. J. 2:1978;1457-1459.
46. Perry R. H. Recent advances in neuropathology. Br. Med. Bull. 42:1986;34-41.
47. Perry R. H., Blessed G., Perry E. K., Tomlinson B. E. Histochemical observations on the cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. Age Ageing. 9:1980;9-16.
48. Rogers G. A., Parsons S. M., Anderson D. C., Nilsson L. M., Bahr B. A., Kornreich W. D., Kaufman R., Jacobs R. S., Kirtman B. Synthesis, in vitro acetylcholine-storage-blocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol). J. Med. Chem. 32:1989;1217-1230.
49. 18F]Vesamicol derivatives for in vivo evaluation as tracers for cholinergic synaptic vesicles. Abstr. IXth International Symposium on Radiopharmaceutical Chemistry, 486; 1992.
50. Roghani A., Feldman J., Kohan S. A., Shirzadi A., Gundersen C. B., Brecha N., Edwards R. H. Molecular cloning of a putative vesicular transporter for acetylcholine. Proc. Natl. Acad. Sci. USA. 91:1994;10620-10624.
51. Rossor M., Iversen L. L. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Br. Med. Bull. 42:1986;70-74.
52. 3H]vesamicol binding in temporal cortex of patients with Alzheimer's disease, Parkinson's disease and rats with basal forebrain lesions. Neuroscience. 35:1990;327-333.
53. Rylett R. J., Ball M. J., Calhoun E. H. Evidence for high-affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res. 289:1984;169-175.
54. Sirvio J., Riekkinen P. J. Brain and cerebrospinal fluid cholinesterases in Alzheimer's disease. Parkinson's disease and aging. A critical review of clinical and experimental studies. J. Neural Transm.[P-D Sect]. 4:1992;337-358.
55. 125I]MIBT binding in monkey brain reveals differences with benzovesamicols. J. Labeled Comp. Radiopharm. 37:1995;370-372.
56. Varoqui H., Diebler M.-F., Meunier F.-M., Rand J. B., Usdin T. B., Bonner T. I., Eiden L. E., Erickson J. D. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo. Homology with the putative vesicular acetylcholine transporter UNC-17 from Caenorhabditis elegans. FEBS Lett. 342:1994;97-102.
57. Wannan G., Prior C., Marshall I. G. α-Adrenoceptor blocking properties of vesamicol. Eur. J. Pharmacol. 201:1991;29-34.
58. Whitehouse P., Price D. L., Stribble R. G., Clark A. W., Coyle J. T., DeLong M. R. Alzheimer's disease and senile dementia loss of neurons in the basal forebrain . Science. 215:1982;1237-1239.
59. Widen L., Eriksson L., Ingvar M., Parsons S. M., Rogers G. A., Stone-Elander S. Positron emission tomographic studies of central cholinergic nerve terminals. Neurosci. Lett. 136:1992;1-4.